Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX or Irinotecan in Patients With Advanced Gastric Cancer
An Open-Label, International, Multicenter, Phase 1b/2a Study to Assess the Safety, Tolerability, and Efficacy of IDX-1197 in Combination With XELOX (Capecitabine and Oxaliplatin) or Irinotecan in Patients With Advanced Gastric Cancer
Sponsor: Idience Co., Ltd.
A observational or N/A phase clinical study on Gastric Cancer, this trial is ongoing. The trial is conducted by Idience Co., Ltd. and has accumulated 11 data snapshots since 2021. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Apr 18, 2026 — Present [daily]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting · Phase: PHASE1/PHASE2 → None
-
Sep 2025 — Apr 2026 [monthly]
Recruiting PHASE1/PHASE2
-
Oct 2024 — Sep 2025 [monthly]
Recruiting PHASE1/PHASE2
Status: Unknown → Recruiting · Phase: PHASE1 → PHASE1/PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Unknown PHASE1
Status: Recruiting → Unknown
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE1
▶ Show 6 earlier versions
-
Sep 2022 — Jul 2024 [monthly]
Recruiting PHASE1
-
Feb 2022 — Sep 2022 [monthly]
Recruiting PHASE1
-
Sep 2021 — Feb 2022 [monthly]
Recruiting PHASE1
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE1
Status: Not Yet Recruiting → Recruiting
-
May 2021 — Jun 2021 [monthly]
Not Yet Recruiting PHASE1
-
Feb 2021 — May 2021 [monthly]
Not Yet Recruiting PHASE1
First recorded
Eligibility Summary
This is an open-label, Phase 1b/2a study to evaluate the safety and tolerability of IDX-1197 and determine the MTD and RP2D in combination with XELOX or irinotecan in patients with advanced gastric cancer.
Contact Information
- Idience Co., Ltd.
For direct contact, visit the study record on ClinicalTrials.gov .